Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Blood Coagulation Disorders/drug therapy"'
Autor:
Reto Stocker, Philippe Lyrer, Reto Basciani, Heinrich Mattle, Marcel Arnold, M. Wasner, Bruno Weder, S. A. Weber, Dimitrios Georgiadis, F. Fluri, C. Staedler, Emanuela Keller, Barbara Tettenborn, Luca Regli, Javier Fandino, Matthias Hänggi, Felix Müller, Patrick Michel, Roman Sztajzel, Krassen Nedeltchev, Stefan T. Engelter, Yvan Gasche, H-J Hungerbuhler, R. Paganoni, Ralf W. Baumgartner
Publikováno v:
European Journal of Cardiovascular Prevention & Rehabilitation, Vol. 4, No 3 (2009) pp. 218-223
P. Michel , M. Arnold, H.-J. Hungerbuhler, F. Muller, C. Staedler, R. W. Baumgartner, D. Georgiadis, P. Lyrer, H. P. Mattle, R. Sztajzel, B. Weder, B. Tettenborn, K. Nedeltchev, S. Engelter, S. A. Weber, R. Basciani, J. Fandino, F. Fluri, R. Stocker,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46228ecabbd56c54a95fc4ca202835e7
https://doi.org/10.1111/j.1747-4949.2009.00283.x
https://doi.org/10.1111/j.1747-4949.2009.00283.x
Autor:
M. Verstraete
clinical efficacy of haemostatic agents had to be published work and had to fulftl most of the following minimum requirements: (1) Quantitation ofthe measured blood loss was required, and not merely a clinical impression of the amount of blood lost,
Autor:
W.N. Drohan, Leon W. Hoyer
Recent progress in molecular biology has led to a rapid expansion of our understanding of the proteins that are essential for hemostasis and thrombosis. The goal of the XXI Annual Scientific Symposium of the American Red Cross was to provide a forum
Publikováno v:
Thrombosis Research, Vol. 122 Suppl 2 (2008) pp. S1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ffdda80746a98f76b4bf98e9c58f57
https://pubmed.ncbi.nlm.nih.gov/18549906
https://pubmed.ncbi.nlm.nih.gov/18549906
Autor:
Wolf-Henning Boehncke, Marc Schindewolf, Roland Kaufmann, Edelgard Lindhoff-Last, Susanne Alban, Ralf Ludwig
Publikováno v:
Thrombosis and Haemostasis, Vol. 94, No 6 (2005) pp. 1265-1269
SummaryEczematous lesions, resulting from type IV sensitizations are well-known and relatively frequent cutaneous adverse effects of s.c. heparin therapy. If anticoagulation is further required intravenous heparin, heparinoids or lepirudin may be use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc519d532c6badeb989c71c44167ae5
https://pubmed.ncbi.nlm.nih.gov/16411404
https://pubmed.ncbi.nlm.nih.gov/16411404
Publikováno v:
Journal of Neurotrauma. 28:689-689
Dear Editor, We read with great interest the recent article by Dudley and associates on early venous thromboembolic event (VTE) prophylaxis in traumatic brain injury (TBI) with lowmolecular-weight heparin (LMWH; Dudley, 2010). In that study the autho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddb73f27882b8680232e192685e69274
https://doi.org/10.1089/neu.2010.1679
https://doi.org/10.1089/neu.2010.1679